Sulfazin500 mg

Sulfazin is a sulfonamide-salicylate compound with established and guideline-supported uses in the following conditions:

FDA-approved / Established Uses

• Ulcerative colitis — for the treatment of mild to moderate disease and as adjunctive therapy in severe disease, and for prolonging the remission period between acute attacks.
• Rheumatoid arthritis (RA) — as a disease-modifying antirheumatic drug (DMARD) for adult patients with active RA who have responded inadequately to salicylates or other NSAIDs.

Guideline-Supported / Commonly Used Off-Label Uses

• Crohn's disease — used, particularly the colonic form, though evidence is less robust than for ulcerative colitis; typically used off-label based on clinical guidelines.
• Juvenile idiopathic arthritis (polyarticular course) — used as a second-line DMARD in pediatric patients under specialist supervision.
• Ankylosing spondylitis and other spondyloarthropathies — used off-label, particularly for peripheral joint involvement, based on rheumatology guideline support.
• Psoriatic arthritis — used off-label as a DMARD option in some patients.

Use of Sulfazin should be initiated and monitored by a physician experienced in managing these conditions.

Sulfazin is a sulfonamide-salicylate compound classified as a disease-modifying antirheumatic drug (DMARD) and as an aminosalicylate used in inflammatory bowel disease. After oral administration, a large portion of Sulfazin reaches the colon largely unabsorbed, where colonic bacteria cleave the azo bond to release its two active components: sulfapyridine, which is absorbed and thought to be primarily responsible for the anti-inflammatory/immunomodulatory effect in rheumatoid arthritis, and 5-aminosalicylic acid (5-ASA), which acts topically within the bowel lumen to reduce mucosal inflammation in inflammatory bowel disease.

Sulfasalazine is split by colonic bacterial azoreductases into sulfapyridine and 5-aminosalicylic acid (5-ASA).

• 5-ASA acts locally on the colonic mucosa, inhibiting prostaglandin and leukotriene synthesis (via cyclooxygenase and lipoxygenase pathway inhibition), scavenging reactive oxygen species, and reducing production of pro-inflammatory cytokines, thereby reducing mucosal inflammation in ulcerative colitis and Crohn's disease.
• Sulfapyridine is well absorbed systemically and is believed to mediate the antirheumatic effect of Sulfasalazine in rheumatoid arthritis, though the exact mechanism of its disease-modifying action is not fully established; effects on immune cell function and cytokine production are thought to contribute.

Absorption, acetylation (genetically determined 'slow' vs 'fast' acetylator status affects sulfapyridine levels and toxicity risk), and renal excretion of sulfapyridine and its metabolites determine much of the drug's systemic pharmacokinetic behavior.

Give with or after food and with a full glass of water to minimize gastrointestinal irritation and reduce crystalluria risk. Swallow enteric-coated/delayed-release tablets whole; do not crush or chew. Space doses evenly through the day and maintain adequate fluid intake throughout treatment.

Sulfazin has several clinically significant drug interactions:

• Folic acid absorption inhibitors / methotrexate: Sulfazin may impair folic acid absorption; combined use with methotrexate may increase the risk of hematologic toxicity — folate supplementation and monitoring are often recommended.
• Warfarin and other oral anticoagulants: Sulfazin may displace warfarin from protein binding and inhibit its metabolism, potentiating anticoagulant effect and increasing bleeding risk; monitor INR closely.
• Digoxin: Sulfazin may reduce digoxin absorption, lowering serum digoxin levels; monitor digoxin levels and clinical response.
• Hepatotoxic or myelosuppressive drugs (e.g., azathioprine, other DMARDs): concurrent use may increase the risk of hepatotoxicity or bone marrow suppression, requiring closer laboratory monitoring.
• Live vaccines: as with other immunomodulating agents, caution is advised as concurrent immunosuppression may reduce vaccine efficacy or increase infection risk.

Common side effects include nausea, vomiting, anorexia, headache, and reversible orange-yellow discoloration of urine, skin, or contact lenses (harmless).

Less common but clinically important effects include:

• Hematologic: leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, and hemolytic anemia (particularly in patients with G6PD deficiency) — these require periodic blood monitoring (see Precautions).
• Hepatic: elevated liver enzymes, hepatitis (rare).
• Dermatologic: rash, photosensitivity, and rare but serious reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
• Renal: crystalluria, proteinuria (rare nephrotic syndrome).
• Reproductive: reversible oligospermia and infertility in men, which resolves after discontinuation.
• Hypersensitivity/serum-sickness-like reactions: fever, rash, lymphadenopathy (DRESS syndrome has been reported rarely).

Patients should seek prompt medical attention for fever, sore throat, unusual bruising/bleeding, jaundice, or severe skin rash while taking Sulfazin.

Sulfazin should be used during pregnancy only if clearly needed, and only if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Sulfazin interferes with folate metabolism, so folic acid supplementation is generally recommended for patients who may become pregnant or are pregnant while on therapy, under physician guidance.

Sulfazin and its metabolite sulfapyridine are excreted in breast milk in small amounts. It is generally considered compatible with breastfeeding in full-term, healthy infants under physician supervision, but caution is advised in premature infants or those with G6PD deficiency or hyperbilirubinemia due to a theoretical risk of kernicterus; consult a physician before use while breastfeeding.

Sulfazin requires the following precautions:

• Hematologic monitoring: Complete blood counts should be obtained periodically (e.g., every 2 weeks for the first 3 months, then periodically thereafter) due to risk of blood dyscrasias such as agranulocytosis, aplastic anemia, and thrombocytopenia, especially during the initial months of therapy.
• Hepatic and renal function: Liver function tests and renal function should be monitored periodically; use with caution in patients with hepatic or renal impairment.
• G6PD deficiency: Use with caution, as hemolytic anemia may occur.
• Slow acetylators: May be at higher risk of dose-related toxicity due to higher circulating sulfapyridine levels.
• Hydration: Maintain adequate fluid intake during therapy to reduce crystalluria risk.
• Male fertility: May cause reversible oligospermia/infertility; discuss with a physician if fertility is a concern.
• Folate deficiency: Long-term use may reduce folate absorption; folic acid supplementation may be advised.
• Hypersensitivity reactions: Discontinue immediately if signs of severe skin reaction, serum sickness, or systemic hypersensitivity occur.

Sulfazin should be taken exactly as prescribed; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Symptoms of Sulfazin overdose may include nausea, vomiting, abdominal pain, drowsiness, and in severe cases, seizures, blood disorders, or metabolic disturbances. There is no specific antidote for Sulfazin overdose. In case of suspected overdose, seek immediate medical attention or contact a poison control center; supportive care and gastric decontamination measures may be provided by medical professionals as appropriate. Do not attempt to treat an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use with caution; elderly patients may be at higher risk of hematologic and renal adverse effects, and closer monitoring is recommended.

Renal impairment: Use with caution and monitor closely, as impaired excretion of sulfapyridine metabolites may increase toxicity risk.

Hepatic impairment: Use with caution; monitor liver function periodically.

G6PD deficiency: Increased risk of hemolytic anemia; use with caution and monitor for signs of hemolysis.

Pediatric patients: See Pediatric Uses section. Contraindicated in infants under 2 months of age.

Aminosalicylates; Disease-Modifying Antirheumatic Drugs (DMARDs); Sulfonamide derivatives

Sulfazin is contraindicated in infants under 2 months of age due to the risk of kernicterus from displacement of bilirubin.

For children 6 years and older, Sulfazin is used for ulcerative colitis (weight-based dosing, see Dosage and Administration) and for polyarticular juvenile idiopathic arthritis as a second-line DMARD, under specialist supervision with regular monitoring of blood counts and liver/renal function.

Safety and efficacy of Sulfazin in children under 6 years of age have not been well established; use only under specialist pediatric guidance.